M-Sympathol
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Explore 128 assets in Peripheral T-Cell Lymphoma, Not Otherwise Specified →Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Affimed GmbH
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05883449CT.gov Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peripheral T-Cell Lymphoma, Not Otherwise Specified
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| M-Sympathol (this asset) | Affimed GmbH | P2 | CCC · 51 |
| Adriamycin | BeBetter Med Inc | P4 | BBB |
| Prednisone | Tarapeutics Science Inc. | P4 | BBB |
| Pralatrexate | Peking University People's Hospital | P4 | BBB |
| (+)-Vincristine | BeBetter Med Inc | P4 | BBB |
| Cyclophosphamide | Tarapeutics Science Inc. | P4 | BBB |
| Romidepsin | University of Virginia | P3 | BBB |
| Rivoceranib | Ruijin Hospital | P4 | BBB |
| Tucidinostat | Ruijin Hospital | P4 | BB |
+42 more in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort
Other indications for M-Sympathol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hypotensive Disorder | — | P4 | BB · 69 |
| Carotid Stenosis | — | P4 | B · 63 |
| Ischemic Stroke | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. M-Sympathol in Peripheral T-Cell Lymphoma, Not Otherwise Specified. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/m-sympathol-peripheral-t-cell-lymphoma-not-otherwise-specified
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →